Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Sold by Baillie Gifford & Co.

Baillie Gifford & Co. decreased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) by 97.5% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 3,358,581 shares of the company’s stock after selling 131,067,285 shares during the quarter. Baillie Gifford & Co. owned about 0.06% of Ginkgo Bioworks worth $27,372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of Ginkgo Bioworks during the second quarter worth approximately $3,391,000. Monaco Asset Management SAM purchased a new position in Ginkgo Bioworks during the 2nd quarter worth $3,276,000. Renaissance Technologies LLC acquired a new position in Ginkgo Bioworks in the second quarter valued at $2,128,000. Cetera Investment Advisers raised its holdings in shares of Ginkgo Bioworks by 2,683.7% in the first quarter. Cetera Investment Advisers now owns 2,264,107 shares of the company’s stock valued at $2,626,000 after buying an additional 2,182,773 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Ginkgo Bioworks during the second quarter worth about $312,000. Hedge funds and other institutional investors own 78.63% of the company’s stock.

Ginkgo Bioworks Price Performance

Shares of NYSE:DNA opened at $8.36 on Wednesday. The firm has a 50-day moving average price of $7.70. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $5.26 and a 52 week high of $75.20.

Wall Street Analysts Forecast Growth

DNA has been the topic of several recent research reports. TD Cowen boosted their price target on Ginkgo Bioworks from $3.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 20th. BTIG Research boosted their target price on Ginkgo Bioworks from $0.20 to $7.00 and gave the company a “sell” rating in a report on Friday, August 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, Ginkgo Bioworks has a consensus rating of “Hold” and a consensus target price of $4.16.

Ginkgo Bioworks Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.